Little Green Pharma Ltd. (AU:LGP) has released an update.
Little Green Pharma Ltd. announces the anticipated shift in US cannabis regulation, as the DEA is set to reclassify cannabis from Schedule I to Schedule III, acknowledging its medical benefits and potentially easing tax burdens on operators. This regulatory milestone, coupled with recent legalization in Germany, has sparked a surge in North American cannabis stocks, with ETFs reflecting the industry seeing over a 25% increase. Such developments are expected to positively impact other cannabis firms, including Little Green Pharma, as market trends suggest a correlation with North American market movements.
For further insights into AU:LGP stock, check out TipRanks’ Stock Analysis page.